 Eiger BioPharmaceuticals, Inc. Nasdaq:EIGR, focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the first patients have been dosed in a Phase 2 study of peginterferon lambda Lambda in outpatients with mild COVID-19 